Adiponectin, leptin, insulin-like growth factor 1, and survivin may predict the inflammatory disease process of early rheumatoid arthritis. The aim is to determine if adiponectin, leptin, IGF-1, and survivin may be biomarkers that predict outcomes for patients with early RA.
- Study Title 1: Serum survivin in early rheumatoid arthritis – results from the SWEFOT trial
- Study Title 2: The SWEFOT trial findings from serum adipokines in early rheumatoid arthritis
Description of the study
This project involves the collection and analysis of stored serum samples from SWEFOT patients and involves collaboration with Elvi Sandberg and Kerstin Brismar of Karolinska Institutet and Malin Erlandsson and Maria Bokarewa of the University of Gothenburg. The purpose of this project would be to find a clear quantitative link between biomarkers (leptin, adiponectin, IGF-1 & survivin) and inflammation in early RA patients, to determine if clinical and radiographic outcomes could be predicted based on biomarker levels – to be compared across treatment groups – and to determine if certain treatments have certain effects on these biomarker levels.
Study 1: Abstracts have been sent to SRF and EULAR 2014
Study 2: Analyses ongoing
Expected to be completed
Study 1: 2014-08-30
Adrian Levitsky, Graduate student
Karen Hambardzumyan (Study 2, adipokines), Saedis Saevarsdottir, Ronald van Vollenhoven
08-517 730 65